Guardant Health appeals Delaware court judgment in TwinStrand patent dispute
GH•Royalty order and product impact
The royalty order covers products that existed at the 2023 trial; current Guardant Reveal and Shield are excluded from potential royalties.
Design changes to Guardant360 have been validated to avoid the impact of potential ongoing royalties.
Appeal filed in Delaware patent case
Guardant Health will appeal a final judgment from the U.S. District Court in Delaware in an intellectual property case brought by TwinStrand Biosciences and the University of Washington.
Execution of the judgment and collection of potential royalties have been stayed pending the appeal.
Related patent challenges remain ongoing
TwinStrand patents were preliminarily invalidated in related U.S. Patent and Trademark Office challenges, and separate Federal Circuit appeals are ongoing.
